London
· Delayed Price · Currency is GBP · Price in USD Q32 Bio Statistics
Total Valuation
Q32 Bio has a market cap or net worth of GBP 34.02 million. The enterprise value is -20.36 million.
| Market Cap | 34.02M |
| Enterprise Value | -20.36M |
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +548.42% |
| Shares Change (QoQ) | +0.94% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 5.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 2.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.45 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.41 |
Financial Position
The company has a current ratio of 6.53, with a Debt / Equity ratio of 1.21.
| Current Ratio | 6.53 |
| Quick Ratio | 6.23 |
| Debt / Equity | 1.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.33 |
| Interest Coverage | -59.53 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -61.10% |
| Return on Capital (ROIC) | -214.37% |
| Revenue Per Employee | -254,403 |
| Profits Per Employee | -1.05M |
| Employee Count | 37 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 17.24 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 24.76 |
| Average Volume (20 Days) | 8,863 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.08 |
Income Statement
In the last 12 months, Q32 Bio had revenue of GBP -10.94 million and -45.22 million in losses. Loss per share was -4.30.
| Revenue | -10.94M |
| Gross Profit | -45.21M |
| Operating Income | -57.74M |
| Pretax Income | -43.82M |
| Net Income | -45.22M |
| EBITDA | -57.37M |
| EBIT | -57.74M |
| Loss Per Share | -4.30 |
Balance Sheet
The company has 66.46 million in cash and 16.49 million in debt, giving a net cash position of 49.97 million.
| Cash & Cash Equivalents | 66.46M |
| Total Debt | 16.49M |
| Net Cash | 49.97M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 13.65M |
| Book Value Per Share | 1.12 |
| Working Capital | 59.33M |
Cash Flow
In the last 12 months, operating cash flow was -49.99 million and capital expenditures -54,465, giving a free cash flow of -50.04 million.
| Operating Cash Flow | -49.99M |
| Capital Expenditures | -54,465 |
| Free Cash Flow | -50.04M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | 527.79% |
| Pretax Margin | 400.58% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Q32 Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -548.42% |
| Shareholder Yield | -548.42% |
| Earnings Yield | -132.92% |
| FCF Yield | -147.09% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Q32 Bio has an Altman Z-Score of -2.12. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.12 |
| Piotroski F-Score | n/a |